Innorna  announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine currently in development by the company.

IN006 is also China's first domestically developed RSV vaccine to enter clinical trials, following IND approval in June 2024. The Phase I trial began with the first subject vaccinated in November 2024. Completion of enrollment and dosing in Phase II marks a milestone toward dose optimization and sets the stage for Phase III efficacy studies.

The Phase II study is a randomized, double-blind, placebo-controlled trial conducted in China among healthy adults aged 60 and above. Key study objectives include dose optimization, broader population validation, and booster evaluation for annual revaccination.

“This Phase II clinical trial marks a critical step in validating IN006’s scientific hypothesis—delivering broad-spectrum, durable protection against RSV,” said Dr. Linxian Li, Founder and CEO of Innorna. “We remain committed to advancing the clinical development of this vaccine candidate efficiently. Our goal is to deliver safer, more effective RNA medicines to meet global public health needs.”